28 research outputs found
An EGFR and AKT Signaling Pathway was Identified with Mediation Model in Osteosarcomas Clinical Study
P208 Pathological complete response (PCR) rates after sequential CT in locally advanced BC
Very high steroid receptor content in postmenopausal breast cancer patient: The unfavorable predictive factor?
375 Breast cancer in the elderly ā epidemiological characteristics and treatment approach
The Biology of Epidermal Growth Factor Receptor and its Value as a Prognostic/predictive Factor
Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients
A pilot study was conducted to assess whether plasma levels of transforming growth factor-beta 1 (TGF-beta 1) might facilitate biological subgrouping of postmenopausal metastatic breast cancer patients, and, accordingly, its applicability in clinical oncology. This study included 29 postmenopausal metastatic breast cancer patients. Plasma TGF-beta 1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Estrogen and progesterone receptors were assayed by radioligand binding, in accordance with the recommendation of the EORTC. Concentrations of 17-beta estradiol were determined by using ELISA-microwell method (DIALAB). Overall survival was followed for 24 months for each individual patient. Stratification of the patients by ER/PR status showed that 14 patients with estrogen receptor-negative, progesterone receptor-negative carcinomas displayed a statistically significant increase in plasma TGF-beta 1 levels when compared to plasma TGF-beta 1 levels of 6 patients with ER-positive, PR-positive carcinomas (P=0.04). In this study, 7 out of 14 patients with negative receptors status had no plasma TGF-beta 1 values overlapping with patients having positive receptors status. The TGF-beta 1 cut-off value was defined as the highest plasma TGF-beta 1 level of ER-positive, PR-positive patients: 3.28 ng/ml. This plasma TGF-beta 1 cut-off value defined low-risk subgroup of 19 patients (! 3.28 ng/ml) and high-risk subgroup of 10 patients ( GT 3.28 ng/ml) (P=0.047). Plasma TGF-beta 1-related survival was independent of the classical prognostic factors of metastatic breast cancer. Accordingly, a clinical significance of elevated plasma TGF-beta 1 levels may be suggested